

# Paolo CalabrÃ²

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4798327/publications.pdf>

Version: 2024-02-01

255  
papers

10,656  
citations

43973

48  
h-index

39575

94  
g-index

256  
all docs

256  
docs citations

256  
times ranked

14311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. <i>Lancet, The</i> , 2015, 385, 2465-2476.	6.3	1,043
2	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020, 41, 2083-2088.	1.0	716
3	Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells. <i>Circulation</i> , 2003, 108, 1930-1932.	1.6	477
4	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2014, 16, 435.	2.0	413
5	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 997-1009.	13.9	334
6	Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways. <i>Circulation</i> , 2004, 110, 3335-3340.	1.6	291
7	Release of C-Reactive Protein in Response to Inflammatory Cytokines by Human Adipocytes: Linking Obesity to Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1112-1113.	1.2	247
8	Atrial Myocardial Deformation Properties Predict Maintenance of Sinus Rhythm After External Cardioversion of Recent-Onset Lone Atrial Fibrillation. <i>Circulation</i> , 2005, 112, 387-395.	1.6	243
9	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	6.3	215
10	The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	1.4	173
11	Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. <i>European Journal of Echocardiography</i> , 2009, 10, 549-555.	2.3	166
12	Hepcidin in Obese Children as a Potential Mediator of the Association between Obesity and Iron Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5102-5107.	1.8	164
13	Left atrial volume index in highly trained athletes. <i>American Heart Journal</i> , 2010, 159, 1155-1161.	1.2	153
14	Prevalence and Clinical Significance of Cardiovascular Abnormalities in Patients With the LEOPARD Syndrome. <i>American Journal of Cardiology</i> , 2007, 100, 736-741.	0.7	150
15	Abnormal myocardial deformation properties in obese, non-hypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. <i>European Heart Journal</i> , 2006, 27, 2689-2695.	1.0	144
16	The pleiotropic effects of statins. <i>Current Opinion in Cardiology</i> , 2005, 20, 541-546.	0.8	138
17	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	1.2	132
18	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. <i>Cardiovascular Research</i> , 2005, 68, 47-55.	1.8	126

#	ARTICLE	IF	CITATIONS
19	Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak. <i>Circulation</i> , 2020, 141, 2035-2037.	1.6	107
20	Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischaemic dilated cardiomyopathy: a two-dimensional speckle strain study. <i>European Heart Journal</i> , 2007, 28, 2738-2748.	1.0	103
21	CRP and the risk of atherosclerotic events. <i>Seminars in Immunopathology</i> , 2009, 31, 79-94.	2.8	103
22	Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. , 2018, 181, 156-168.		102
23	Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 1.	1.2	102
24	Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. <i>International Journal of Obesity</i> , 2010, 34, 1772-1774.	1.6	94
25	Obesity, Inflammation, and Vascular Disease. <i>Sub-Cellular Biochemistry</i> , 2007, , 63-91.	1.0	82
26	Association between left atrial myocardial function and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy: A two-dimensional speckle strain study. <i>International Journal of Cardiology</i> , 2009, 132, 354-363.	0.8	81
27	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	1.1	81
28	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
29	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. <i>Cardiovascular Diabetology</i> , 2019, 18, 24.	2.7	78
30	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. <i>European Heart Journal</i> , 2015, 36, 1242-1251.	1.0	76
31	Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. <i>Cardiovascular Diabetology</i> , 2022, 21, 77.	2.7	76
32	Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. <i>Internal and Emergency Medicine</i> , 2009, 4, 25-34.	1.0	75
33	Peri-Procedural Tight Glycemic Control during Early Percutaneous Coronary Intervention Is Associated with a Lower Rate of In-Stent Restenosis in Patients with Acute ST-Elevation Myocardial Infarction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2862-2871.	1.8	73
34	Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk. <i>Current Hypertension Reports</i> , 2008, 10, 32-38.	1.5	72
35	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 375-388.	1.2	70
36	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. <i>Atherosclerosis</i> , 2018, 269, 219-228.	0.4	67

#	ARTICLE	IF	CITATIONS
37	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal-Regulated Kinase Activation. <i>Circulation</i> , 2004, 109, 2911-2916.	1.6	63
38	Thyroid function derangement and childhood obesity: an Italian experience. <i>BMC Endocrine Disorders</i> , 2010, 10, 8.	0.9	61
39	Radiation Exposure and Vascular Access in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2530-2537.	1.2	61
40	Effect of dynamic myocardial dyssynchrony on mitral regurgitation during supine bicycle exercise stress echocardiography in patients with idiopathic dilated cardiomyopathy and 'narrow' QRS. <i>European Heart Journal</i> , 2007, 28, 1004-1011.	1.0	60
41	Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 1311-1318.	1.0	59
42	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF- $\kappa$ B-Dependent Pathway. <i>Journal of Vascular Research</i> , 2011, 48, 59-66.	0.6	58
43	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 299, 186-191.	0.8	58
44	Venous thromboembolism and lung cancer: a review. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 28.	0.6	56
45	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , 2017, 34, 1200-1210.	1.3	56
46	Global longitudinal speckle-tracking strain is predictive of left ventricular remodeling after coronary angioplasty in patients with recent non-ST elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2011, 153, 185-191.	0.8	55
47	Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 4-16.	0.9	55
48	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	1.0	53
49	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 151-161.	0.6	53
50	Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 142-148.	0.9	50
51	Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. <i>Cardiovascular Diabetology</i> , 2018, 17, 152.	2.7	48
52	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5863.	1.8	48
53	Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 620-628.	0.7	47
54	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	1.1	47

#	ARTICLE	IF	CITATIONS
55	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380.	2.6	46
56	Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 755.	0.5	45
57	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. <i>BMJ</i> , The, 2016, 354, i4935.	3.0	43
58	Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E518-E526.	0.7	43
59	Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. <i>Frontiers in Pediatrics</i> , 2021, 9, 632293.	0.9	43
60	Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1030-E1035.	1.8	42
61	Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 101-111.	1.1	42
62	Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108959.	1.1	42
63	Adipose tissue and vascular inflammation in coronary artery disease. <i>World Journal of Cardiology</i> , 2014, 6, 539.	0.5	42
64	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 96-108.	1.8	40
65	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 67-75.	1.0	40
66	Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2248-2255.	1.9	39
67	Right Ventricular Myocardial Function in Patients with Either Idiopathic or Ischemic Dilated Cardiomyopathy Without Clinical Sign of Right Heart Failure: Effects of Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1017-1029.	0.5	39
68	A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy. <i>Clinical Genetics</i> , 2009, 76, 91-101.	1.0	39
69	C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 152, 7-12.	0.8	39
70	Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 416-433.	0.4	39
71	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 556-558.	0.8	39
72	Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1117-1127.	1.1	38

#	ARTICLE	IF	CITATIONS
73	Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. International Journal of Molecular Sciences, 2020, 21, 6462.	1.8	38
74	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. Journal of the American College of Cardiology, 2001, 38, 569-576.	1.2	37
75	Acute kidney injury after percutaneous coronary intervention: Rationale of the <scp>AKI&Mdash;</scp>MATRIX</scp> (acute kidney injury&Mdash;minimizing adverse hemorrhagic events by TRansradial access site and systemic) Tj ETQq1 1 0.784314 ggBT /Ov 0.7	0.7	37
76	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Internal and Emergency Medicine, 2019, 14, 621-625.	1.0	37
77	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	0.8	35
78	von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications. Seminars in Thrombosis and Hemostasis, 2018, 44, 249-260.	1.5	35
79	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	0.8	35
80	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
81	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	0.8	34
82	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. Journal of Cardiovascular Medicine, 2018, 19, 75-77.	0.6	34
83	The role of adiposity as a determinant of an inflammatory milieu. Journal of Cardiovascular Medicine, 2008, 9, 450-460.	0.6	33
84	Effects of Transcatheter Aortic Valve Implantation on Left Ventricular and Left Atrial Morphology and Function. Echocardiography, 2015, 32, 928-936.	0.3	33
85	Hypertrophic Cardiomyopathy in RASopathies. Heart Failure Clinics, 2022, 18, 19-29.	1.0	33
86	The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients. Journal of Cardiovascular Electrophysiology, 2016, 27, 65-72.	0.8	32
87	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute&Mdash;Coronary&Mdash;Syndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	1.2	32
88	Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?. European Heart Journal, 2019, 40, 216-217.	1.0	32
89	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. International Journal of Environmental Research and Public Health, 2021, 18, 904.	1.2	32
90	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. Journal of Cardiovascular Pharmacology, 2020, 76, 173-180.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 63-91.	1.0	31
92	Left ventricular remodeling, mechanics, and tissue characterization in congenital aortic stenosis. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 214-220.	1.2	30
93	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 1.	1.1	28
94	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	0.8	28
95	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. <i>Current Vascular Pharmacology</i> , 2017, 15, 404-415.	0.8	28
96	Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. <i>Internal and Emergency Medicine</i> , 2012, 7, 425-430.	1.0	27
97	The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1249.	1.2	27
98	HMG-CoA Reductase Inhibitors Reduce Nicotine-Induced Expression of Cellular Adhesion Molecules in Cultured Human Coronary Endothelial Cells. <i>Journal of Vascular Research</i> , 2007, 44, 460-470.	0.6	25
99	Takotsubo Cardiomyopathy. <i>Heart Failure Clinics</i> , 2013, 9, 207-216.	1.0	25
100	Laboratory medicine: health evaluation in elite athletes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1450-1473.	1.4	25
101	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. <i>Atherosclerosis</i> , 2020, 312, 72-78.	0.4	25
102	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 361-373.	1.1	25
103	Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 951-962.	0.6	24
104	Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 435-447.	0.6	24
105	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014, 26, 563-9.	0.4	24
106	Activated platelets stimulate tissue factor expression in smooth muscle cells. <i>Thrombosis Research</i> , 2003, 112, 51-57.	0.8	23
107	Hypertrophic cardiomyopathy in a girl with Cornelia de Lange syndrome due to mutation in <i>SMC1A</i> . <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 2127-2129.	0.7	23
108	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9424.	1.2	23

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.	0.8	23
110	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	1.0	22
111	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 758-774.	1.2	22
112	Left Ventricular Non Compaction in Children. <i>Congenital Heart Disease</i> , 2010, 5, 384-397.	0.0	21
113	A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. <i>International Journal of Cardiology</i> , 2016, 224, 454-455.	0.8	21
114	From Femoral to Radial Approach in Coronary Intervention. <i>Angiology</i> , 2017, 68, 281-287.	0.8	21
115	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019, 70, 257-263.	0.8	21
116	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
117	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2017, 12, e0186961.	1.1	21
118	Inhibition of Tumor-Necrosis-Factor-Induced Endothelial Cell Activation by a New Class of PPAR- $\beta$ Agonists. <i>Journal of Vascular Research</i> , 2005, 42, 509-516.	0.6	20
119	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
120	Genetics of Takotsubo Syndrome. <i>Heart Failure Clinics</i> , 2016, 12, 499-506.	1.0	19
121	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. <i>International Journal of Cardiology</i> , 2021, 325, 109-114.	0.8	19
122	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018, 259, 20-25.	0.8	18
123	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. <i>International Journal of Cardiology</i> , 2018, 273, 8-14.	0.8	18
124	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. <i>Heart Failure Clinics</i> , 2022, 18, 39-49.	1.0	18
125	Echocardiographic Evaluation of Left Ventricular Systolic Function in the Down Syndrome 22Dr. Bruno Marino is supported by Telethon-Italy n. E.C. 496.. <i>American Journal of Cardiology</i> , 1998, 81, 1215-1217.	0.7	17
126	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX " Radiation Dose study (RAD-MATRIX). <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 209-213.	0.3	17



#	ARTICLE	IF	CITATIONS
127	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019, 14, e0219676.	1.1	16
128	The Risk of Sudden Unexpected Cardiac Death in Children. <i>Heart Failure Clinics</i> , 2022, 18, 115-123.	1.0	16
129	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	1.0	14
130	Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA). <i>International Journal of Cardiology</i> , 2022, 354, 7-13.	0.8	14
131	Cardiotrophin-1 and TNF- $\alpha$ circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. <i>Cytokine</i> , 2010, 50, 245-247.	1.4	13
132	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 83-90.	0.6	13
133	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. <i>PLoS ONE</i> , 2020, 15, e0233050.	1.1	13
134	The athlete's heart and hypertrophic cardiomyopathy: two conditions which may be misdiagnosed and coexistent. Which parameters should be analysed to distinguish one disease from the other?. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 257-266.	0.6	12
135	Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. <i>Internal and Emergency Medicine</i> , 2011, 6, 503-507.	1.0	12
136	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2018, 122, 936-943.	0.7	12
137	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	1.2	12
138	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 73-87.	1.0	12
139	Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. <i>International Journal of Cardiology</i> , 2022, 354, 22-28.	0.8	12
140	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. <i>Thrombosis Research</i> , 1999, 96, 329-333.	0.8	11
141	Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 992-998.	1.9	11
142	Diffuse coronary dilation in a young patient with LEOPARD syndrome. <i>International Journal of Cardiology</i> , 2006, 112, E35-E37.	0.8	11
143	Evidence of right coronary from mid-left anterior descending coronary: a rare case of coronary anomalous origin. <i>European Heart Journal</i> , 2009, 30, 565-565.	1.0	11
144	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 425-430.	0.3	11

#	ARTICLE	IF	CITATIONS
145	Childhood obesity: an overview of laboratory medicine, exercise and microbiome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1385-1406.	1.4	11
146	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. <i>Diagnostics</i> , 2021, 11, 2144.	1.3	11
147	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2004, 6, 36-41.	2.0	10
148	Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on $\beta_1$ and $\beta_2$ -adrenergic receptors polymorphisms?. <i>International Journal of Cardiology</i> , 2015, 199, 189-192.	0.8	10
149	Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Tj ETQq1 1 0.784314 rgBT /Overl	0.7	10
150	Feasibility and usefulness of right ventricular ultrasonic tissue characterization with integrated backscatter in patients with unsuccessfully operatively $\alpha$ -repaired $\alpha$ -tetralogy of Fallot. <i>American Journal of Cardiology</i> , 2002, 90, 669-671.	0.7	9
151	Clinical Outcome in Patients with Intermediate Stenosis of Left Anterior Descending Coronary Artery after Deferral of Revascularization on the Basis of Noninvasive Coronary Flow Reserve Measurement. <i>Echocardiography</i> , 2009, 26, 431-440.	0.3	9
152	Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation. <i>Hypertension Research</i> , 2011, 34, 790-791.	1.5	9
153	Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. <i>Internal and Emergency Medicine</i> , 2014, 9, 43-50.	1.0	9
154	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reporative Therapy) Prospective Multicenter Pilot Study. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 40-48.	1.1	9
155	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 355-361.	1.0	9
156	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 642-651.	0.7	9
157	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
158	Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. <i>Pediatric Cardiology</i> , 2021, 42, 1133-1140.	0.6	9
159	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1684-1689.	1.1	8
160	Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 711-713.	0.6	8
161	Diagnosis and Management of Atrial Fibrillation by Primary Care Physicians in Italy. <i>Clinical Drug Investigation</i> , 2012, 32, 771-777.	1.1	8
162	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 580-589.	0.6	8

#	ARTICLE	IF	CITATIONS
163	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	0.8	8
164	Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. <i>Future Cardiology</i> , 2021, 17, 647-654.	0.5	8
165	Methicillin-Resistant <i>Staphylococcus aureus</i> : Risk for General Infection and Endocarditis Among Athletes. <i>Antibiotics</i> , 2020, 9, 332.	1.5	8
166	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.	0.8	8
167	Which Hemodynamic Parameter Predicts Nitroglycerin-Potentiated Head-Up Tilt Test Response?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 507-513.	0.5	7
168	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. <i>American Heart Journal</i> , 2018, 196, 113-118.	1.2	7
169	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.4	7
170	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 559-570.	1.0	7
171	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 893-901.	0.4	7
172	Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e36-e38.	0.8	7
173	Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry). <i>International Journal of Cardiology</i> , 2018, 258, 50-54.	0.8	6
174	Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study). <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 668-677.	0.7	6
175	Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov) <a href="https://doi.org/10.7843/14.7gBT/Overlock">Tj ETQq1 1 0.784314.7gBT /Overlock 1</a>	1.0	6
176	Perioperative care of cardiac patient's candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines. <i>Internal and Emergency Medicine</i> , 2018, 13, 1185-1190.	1.0	6
177	Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2116-2118.	1.1	6
178	Event recurrence after myocardial infarction: Prediction is very difficult, especially about the future. <i>International Journal of Cardiology</i> , 2019, 296, 30-31.	0.8	6
179	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	6
180	Advanced Heart Failure in Special Population - Pediatric Age. <i>Heart Failure Clinics</i> , 2021, 17, 673-683.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Clinical Course and Risk Profile in Adolescents With Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 105, 716-720.	0.7	5
182	ST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy. <i>European Journal of Internal Medicine</i> , 2015, 26, 144-145.	1.0	5
183	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 465-472.	1.3	5
184	Cardiovascular calcification and subcortical bone demineralization in hypertension. <i>Hypertension Research</i> , 2017, 40, 825-830.	1.5	5
185	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 575-588.	0.9	5
186	Lugar de acceso y tipo de anticoagulante en pacientes con sÃndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 893-901.	0.6	5
187	Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome. <i>Cardiology in the Young</i> , 2020, 30, 663-667.	0.4	5
188	Severe, early onset hypertrophic cardiomyopathy in a family with LEOPARD syndrome. <i>Journal of Prenatal Medicine</i> , 2008, 2, 24-6.	0.2	5
189	Thoracic Aortic Dilation: Implications for Physical Activity and Sport Participation. <i>Diagnostics</i> , 2022, 12, 1392.	1.3	5
190	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. <i>Clinical Cardiology</i> , 0, , .	0.7	5
191	Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight in the global cardiometabolic risk. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 32-38.	0.8	4
192	â€œFull-plastic jacketâ€ with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). <i>International Journal of Cardiology</i> , 2018, 266, 67-74.	0.8	4
193	Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation. <i>Biomolecules</i> , 2021, 11, 696.	1.8	4
194	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1170-1179.	0.4	4
195	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. <i>International Journal of Cardiology</i> , 2022, 349, 31-38.	0.8	4
196	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
197	Radial Versus Femoral Access for Coronary Angiography. <i>Angiology</i> , 2018, 69, 286-287.	0.8	3
198	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolongedâ€Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	2.3	3

#	ARTICLE	IF	CITATIONS
199	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , 2020, 71, 235-241.	0.8	3
200	Rare case of Kawasaki disease with cardiac tamponade and giant coronary artery aneurysms. <i>Cardiology in the Young</i> , 2021, 31, 865-866.	0.4	3
201	Nuclear factor-kappa B predicts long-term clinical outcome in patients with hypertrophic cardiomyopathy: 10-year follow-up study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e108-e111.	0.8	3
202	Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1488-1500.	0.8	3
203	Management of Patients With Asymptomatic Severe Aortic Stenosis and Severe Anemia. <i>American Journal of Cardiology</i> , 2010, 105, 423.	0.7	2
204	Letter by Calabrà <sup>2</sup> and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials". <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	2
205	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Trial. <i>Cardiovascular Interventions</i> , 2020, 96, 1156-1171.	0.7	2
206	Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?. <i>European Heart Journal</i> , 2020, 41, 2332-2332.	1.0	2
207	Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 1721.	1.0	2
208	Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter. <i>International Journal of Cardiology</i> , 2021, 339, 243-245.	0.8	2
209	Inflammation, C-Reactive Protein, and Vulnerable Plaques. , 2007, , 611-620.		2
210	Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience. <i>Current Vascular Pharmacology</i> , 2018, 17, 92-98.	0.8	2
211	Natural history of left ventricular hypertrophy in infants of diabetic mothers. <i>International Journal of Cardiology</i> , 2022, 350, 77-82.	0.8	2
212	Anticoagulation After Primary PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 264-267.	1.1	2
213	Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. <i>Journal of Cardiovascular Echography</i> , 2021, 31, 157-164.	0.1	2
214	Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 3574.	1.0	2
215	Inflammation: The Link Between Obesity and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 101-111.	0.8	1
216	Which is the correct management of patients with asymptomatic severe calcific aortic stenosis after symptomatic spontaneous calcium cerebral embolism?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 428-429.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Contemporary evidence of coronary atherosclerotic disease and myocardial bridge on left anterior descending artery in a patient with a nonobstructive hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 510-512.	0.6	1
218	Rapid ultrasound score as an indicator of atherosclerosisâ€™ clinical manifestations in a population of hypertensives. <i>Anatolian Journal of Cardiology</i> , 2013, 14, 9-15.	0.4	1
219	Preoperative evaluation before MitraClip<sup>Â®</sup>: present and future perspective. <i>Future Cardiology</i> , 2014, 10, 725-744.	0.5	1
220	Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 520-521.	0.6	1
221	Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?. <i>American Journal of Medicine</i> , 2017, 130, e515.	0.6	1
222	Simulation Models of Therapy Intensification in Lipid-Lowering Medicine. <i>JAMA Cardiology</i> , 2018, 3, 88.	3.0	1
223	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlook 1143-1150.	0.7	1
224	Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. <i>Pharmaceuticals</i> , 2021, 14, 290.	1.7	1
225	Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 424-426.	0.8	1
226	Coronary stent thickness: thinner is (always) better for all lesions?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 26-28.	0.6	1
227	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 278-280.	0.6	1
228	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. <i>Neurology International</i> , 2021, 11, 230-254.	0.2	1
229	Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. <i>Neurology International</i> , 2022, 12, 102-108.	0.2	1
230	Potential clinical perspectives of Doppler myocardial imaging and strain rate imaging during stress echocardiography. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 480-490.	0.6	0
231	A new character on the scene of cardiorenal syndrome. <i>Hypertension Research</i> , 2011, 34, 996-996.	1.5	0
232	Routine evaluation of abdominal aorta diameter at the end of transthoracic echocardiography in hypertensive patients. Why not?. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 748-749.	0.6	0
233	Atypical â€œvacuumâ€ inside of neoatherosclerosis long term after DES implantation: Insights from optical coherence tomography. <i>International Journal of Cardiology</i> , 2015, 199, 221-222.	0.8	0
234	Pathogenesis of Takotsubo Syndrome. <i>Neurology International</i> , 2016, 6, 5973.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Letter by Natale et al Regarding Article, "Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort)" Tj ETQq1 1 0.784314 rgBT /@verlock 10		
236	Letter by Calabrà <sup>2</sup> et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" Circulation, 2018, 138, 218-219.	1.6	0
237	Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuloplasty guided by low dose of radiation: a case report and brief overview. General Thoracic and Cardiovascular Surgery, 2021, 69, 364-366.	0.4	0
238	Genetic Susceptibility to SARS-CoV-2: From the Neanderthal Age to 2020. Neurology International, 2021, 11, 28-30.	0.2	0
239	Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	0
240	Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access. , 2020, , 85-101.		0
241	Long-Term Variation in Kidney Function and Its Impact After Acute Myocardial Infarction. American Journal of Cardiology, 2021, , .	0.7	0
242	Prognostic implications of ischemia with nonobstructive coronary arteries: Understanding risks for improving treatment. Journal of Internal Medicine, 2022, 291, 112-114.	2.7	0
243	CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	0
244	585 Natural history of left ventricular hypertrophy in infants of diabetic mothers. European Heart Journal Supplements, 2021, 23, .	0.0	0
245	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 1945.	1.0	0
246	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization. Journal of Clinical Medicine, 2022, 11, 2091.	1.0	0
247	589 External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.0	0
248	Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical Implications. Current Vascular Pharmacology, 2022, 20, 318-320.	0.8	0
249	Title is missing!. , 2020, 15, e0233050.		0
250	Title is missing!. , 2020, 15, e0233050.		0
251	Title is missing!. , 2020, 15, e0233050.		0
252	Title is missing!. , 2020, 15, e0233050.		0

#	ARTICLE	IF	CITATIONS
253	Title is missing!. , 2020, 15, e0233050.		0
254	Title is missing!. , 2020, 15, e0233050.		0
255	Optimal opportunistic screening of atrial fibrillation using pulse palpation in cardiology outpatient clinics: Who and how. PLoS ONE, 2022, 17, e0266955.	1.1	0